All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

  TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub
Brought to you by Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ALL Drug Updates

Stay up to date with all the latest drug and trial news reported from our X account.

Popular:

 | 
X post image
🚨 NEWS 🚨 The CHMP of the EMA has recommended the approval of obecabtagene autoleucel for the treatment of patients aged ≥26 years with relapsed/refractory B-ALL, based on data from the phase Ib/II FELIX study. https://loom.ly/RVyVUL4 #ALL #ALLsm #leusm #MedNews @EMA_News
Show on  
X post image
🚨 NEWS 🚨 The UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization to obecabtagene autoleucel, an autologous anti-CD19 CAR T-cell therapy, for the treatment of adult patients with R/R B-ALL. Read more here👉 https://loom.ly/IgpypQo #leusm #ALLsm #MedNews
Show on  
X post image
🚨 News 🚨 NICE recommends blinatumomab with consolidation chemotherapy for patients with Ph− CD19+ MRD− B-ALL in the UK. Read more: https://loom.ly/mbukx0w #leusm #ALLsm #MedNews
Show on  
X post image
🚨 News 🚨 Olverembatinib granted Breakthrough Therapy Designation by China’s NMPA CDE for the treatment of patients with ND Ph+ ALL in combination with low-intensity chemotherapy. Read more: https://loom.ly/ukDrlJE #MedNews #leusm #ALLsm
Show on  
X post image
🚨 News 🚨 @US_FDA clears an IND application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with R/R T-ALL/LBL. Read more: https://loom.ly/cLDTYEs #MedNews #leusm #ALLsm
Show on  
X post image
🚨 NEWS 🚨  The European Commission approved blinatumomab, a bispecific T-cell engager, as part of consolidation therapy for the treatment of adult patients with newly diagnosed Ph− CD19+ B-ALL.  Read more here: https://loom.ly/GWnSrVw#leusm #ALLsm #MedNews
Show on  
X post image
🚨 NEWS 🚨 @US_FDA has approved an oral solution formulation of imatinib to treat certain forms of leukemia including #ALL, CML, MDS/MPD, and gastrointestinal tumors. 👉 https://loom.ly/ab29hIc #ALLsm #leusm
Show on  
X post image
🚨 NEWS 🚨 @US_FDA approves revumenib for the treatment of pediatric patients aged ≥1 year with R/R ALL and a KMT2A translocation. This approval was based on results from the multicenter, open-label AUGMENT-101 study. Read more: https://loom.ly/3XbhErU #allsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 The @US_FDA expands oral methotrexate approval to include the treatment of pediatric patients with acute lymphoblastic leukemia. Read more here 👉 https://loom.ly/ECfdwnU #ALLsm #leusm #MedNews #MedEd
Show on  
X post image
🚨 NEWS 🚨 The @US_FDA grants Investigational New Drug application status to VNX-101, a gene therapy product candidate, for the treatment of #ALL. A phase I/II trial of VNX-101 will start enrolling patients in the Q4 of 2024 👉 https://loom.ly/h9fzOko #allsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 Topline data from a real-world study of ORG-101, a CAR T-cell therapy, showed positive efficacy and safety outcomes in patients with CD19+ B-cell #ALL. Read the key data here: https://loom.ly/7AYuiio #ALLsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 The @US_FDA grants orphan drug designation to alemtuzumab, an anti-CD52 antibody, as part of the lymphodepletion regimen for the treatment of relapsed/refractory B-cell #ALL. 👉 https://loom.ly/xouUNJ4 #ALLsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 The @US_FDA grants orphan drug & rare pediatric disease designation status to UCART22, an allogeneic CAR T-cell product candidate targeting CD22, for the treatment of #ALL based on data from the phase I/2 BALLI-01 trial 👉 https://loom.ly/SBIU_48 #allsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 @US_FDA grants rare disease designation to SLS009, an investigational highly selective CDK9 inhibitor, for the treatment of pediatric ALL based on the favorable safety profile of SLS009 in clinical trials. Read more 👉 https://loom.ly/8UVxgeY #ALLsm #leusm #MedNews
Show on  
X post image
🚨 NEWS 🚨 @US_FDA approves blinatumomab for patients aged ≥1 month who have CD19-positive, Ph– B-ALL in the consolidation phase, irrespective of MRD status, based on results from the phase III ECOG-ACRIN E1910 study. Read more here: https://t.co/ud3RhkLn0I #ALL #ALLsm #leusm
Show on